Alpha 2.0
Login Register
» Authors » Anne J Grotenhuis

Anne J Grotenhuis

Explore the profile of Anne J Grotenhuis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 564
Followers 0
Related Specialties
Urology
General Medicine
Oncology
Top 10 Co-Authors
Sita H Vermeulen
Lambertus A Kiemeney
J Alfred Witjes
Gerald W Verhaegh
Katja K Aben
Aleksandra M Dudek
Nuria Malats
Alina Vrieling
Maurice P Zeegers
Lambertus A L M Kiemeney
Published In
PLoS One
Hum Mol Genet
Curr Opin Urol
Int J Cancer
PLoS Pathog
Affiliations
Soon will be listed here.
Recent Articles
1.
Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial
Vos C, Ter Hark S, Schellekens A, Spijker J, van der Meij A, Grotenhuis A, et al.
JAMA Netw Open . 2023 May; 6(5):e2312443. PMID: 37155164
Importance: Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT) with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs), pharmacogenetics may be of interest because therapeutic plasma concentrations are...
2.
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer
Galesloot T, Grotenhuis A, Kolev D, Aben K, Bryan R, Catto J, et al.
Eur Urol Oncol . 2021 Aug; 5(1):70-83. PMID: 34353775
Background: Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrences and a risk of progression in stage and grade. Increased knowledge of underlying biological mechanisms is needed. Objective: To identify...
3.
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer
DAndrea D, Soria F, Grotenhuis A, Cha E, Malats N, Di Stasi S, et al.
World J Urol . 2021 Mar; 39(9):3337-3344. PMID: 33713162
Purpose: To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC). Materials And Methods:...
4.
No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression
Evers J, Grotenhuis A, Aben K, Kiemeney L, Vrieling A
PLoS One . 2020 Mar; 15(3):e0229384. PMID: 32210471
Background: Non-muscle invasive bladder cancer patients are at high risk for tumour recurrence and progression, hence an intensive follow-up procedure is recommended which is costly. Identification of factors that are...
5.
Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk
Dudek A, Vermeulen S, Kolev D, Grotenhuis A, Kiemeney L, Verhaegh G
Cell Oncol (Dordr) . 2018 Jun; 41(5):555-568. PMID: 29956121
Purpose: Genome-wide association studies (GWAS) have led to the identification of a bladder cancer susceptibility variant (rs710521) in a non-coding intergenic region between the TP63 and LEPREL1 genes on chromosome...
6.
Smoking intensity and bladder cancer aggressiveness at diagnosis
Barbosa A, Vermeulen S, Aben K, Grotenhuis A, Vrieling A, Kiemeney L
PLoS One . 2018 Mar; 13(3):e0194039. PMID: 29570711
Objective: To explore the relation between cigarette smoking intensity and bladder cancer aggressiveness at first diagnosis. Methods: Patients diagnosed with urinary bladder cancer (BC) between 1995-2011 under the age of...
7.
Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response
Grotenhuis A, Dudek A, Verhaegh G, Aben K, Witjes J, Kiemeney L, et al.
Bladder Cancer . 2016 Jul; 2(1):77-89. PMID: 27376129
Background: Many studies investigated the prognostic or predictive relevance of single nucleotide polymorphisms (SNPs) in biologically plausible genes in urinary bladder cancer (UBC) patients. Most published SNP associations have never...
8.
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin
Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, et al.
BJU Int . 2015 Oct; 118(1):44-52. PMID: 26469362
Objectives: To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes...
9.
Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer
Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, Kumar V, et al.
PLoS Pathog . 2014 Oct; 10(10):e1004485. PMID: 25356988
The anti-tuberculosis-vaccine Bacillus Calmette-Guérin (BCG) is the most widely used vaccine in the world. In addition to its effects against tuberculosis, BCG vaccination also induces non-specific beneficial effects against certain...
10.
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients
Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al.
Eur Urol . 2014 Jul; 67(1):74-82. PMID: 25043942
Background: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. Objective: To assess prognostic factors in patients who received bacillus...